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O
ne of the most important findings to come out of the
landmark Framingham Heart Study was the develop-
ment of tools to predict patients’ risk of developing coronary
artery disease (CHD).
1 By analyzing data across multiple CHD
risk factor categories derived from this prospective cohort, it
became possible to predict patients’ 10-year risk for CHD; the
prediction model was based on a set of parameter estimates for
each risk factor and combinations of risk factors.
2 Wilson et al.
recognized if physicians were to use these tools for clinical
decision-making that they needed to be quick and easy to use.
In 1998, they published the sex-specific Framingham Risk
Scoring (FRS) system.
3 FRS involved converting the parameter
estimates from the original prediction model into whole
numbers (points) that could then be summed and converted
into a 10-year risk. Scoring algorithms using these points are
available in print, online and through hand-held electronic
devices. Use of FRS point scoring was promulgated in the Third
Adult Treatment Panel (ATP III) recommendations for treat-
ment of high cholesterol by the National Cholesterol Education
Program.
4 FRS arguably represents the most widely used
validated-tool for personalized clinical decision making.
In a provocative study, Gordon et al. compared the risk
classification of FRS point scoring with the original Framingham
predictionmodelusingriskfactorprevalenceinformationderived
from the National Health and Nutrition Survey (NHANES) 2001–
2006.
5 They observed significant discrepancies between the two
methods. Relative to the original model, point counting reclassi-
fies a large percentage of patients into risk categories that could
potentially alter treatment eligibility based on ATP III recommen-
dations; notably, use of the counting system instead of the
original parameter estimates resulted in 5% of patients being
“under-treated” and 10% being “over-treated” (assuming the
original parameter estimates represent the gold standard). While
theauthorsdonotcomparetheactualperformanceofthesetools,
theyarguethatitisimplausible thata simplifiedversionin which
parameter estimates are rounded to the nearest whole number
would outperform the original, more sophisticated version. They
further suggest that widespread use of electronic devices
including those loaded with FRS software make it feasible to
use the original Framingham model to estimate risk, essentially
rendering point scoring a relic of the pre-electronic age.
Are their findings valid? Consistent with ATP III guidelines,
Gordon et al. excluded those with low risk and known CHD (or
CHD equivalent) disease from the analysis, thus sharpening
the contrast between the two models by focusing on those in
the intermediate risk range. Patients taking lipid-lowering
therapy were excluded because FRS was not designed to
assess risk among persons receiving drug treatment. However,
this exclusion creates a non-representative sample. Potentially,
persons who were treated based on use of FRS point scoring
were excluded from further analysis. The impact of this bias is
hard to quantify, but given that only 11% of the study sample
were affected, it seems unlikely that this exclusion would
significantly alter their findings, particularly among those in
the intermediate risk categories where drug treatment is less
frequent. Gordon et al. confined their sample to those with two
or more major risk factors. Had they included all untreated
adults with complete data and compared the original FRS
model to point scoring using for the ATP III two-step procedure,
even greater discrepancies may have been noted as suggested
by an analysis of earlier NHANES.
6 Thus, on balance it appears
that the authors’ conclusion regarding significant discrepancies
in CHD risk or “misclassification” is justified.
Are their recommendations sound? Do these observed
discrepancies affect patient outcomes? Is it time to incorporate
the original Framingham prediction model into electronic
versions of FRS? Studies have suggested that the proper use
of assessment tools improves outcomes. In the absence of
formal risk assessment, physicians often misjudge CHD risk.
7
A meta-analysis showed that CHD risk assessment improves
patient outcomes and reduces harm.
8 Nonetheless, Wilson et
al.’s hope that most physicians would actually use FRS point
scoring has not been realized. In fact, most physicians do not
use any type of FRS.
9,10 Furthermore, even when CHD risk
scores are appended to patients’ charts, most physicians do
not alter their clinical decision-making.
11 In the context of
current medical practice, discrepancies between these models
may have relatively little impact on patient outcomes because
physicians typically do not use FRS point counting or FRS-
based on more precise parameter estimates.
But, medical practice is at the cusp of an electronic
transformation aided by rapidly evolving technology, recent
federal standards, and financial incentives for “meaningful
use” of electronic health records (EHRs).
12 The recent appoint-
ment of health care improvement maven Donald Berwick to
head the Centers for Medicare and Medicaid Services may also
herald the acceleration of the use of technology to improve
quality. Adoption of EHRs by community physicians is rapidly
approaching the tipping point. By 2009, 44% of office Published online August 10, 2010
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1140physicians in the US reported use of some type of EHR.
13 EHRs
make it technically feasible to automatically generate CHD risk
assessments and identify patients in need of interventions.
14,15
Increasingly, EHR data will also be used to monitor (and
potentially improve) physician performance. These same data
will also be fodder for malpractice claims. Physicians who
choose to deviate from embedded clinical decision support
systems that include risk assessment and corresponding
specific clinical recommendations will be expected to document
their reasons for doing so.
In this rapidly evolving environment for medical practice,
simple point scoring systems may have seen their day. As
Gordon et al. suggest, EHRs and portable electronic devices
enable risk tools that require complex computations. EHRs
could also facilitate tailoring risk assessment-based social and
other novel risk factors. For example, consideration of SES
improves risk calibration, particularly for low socioeconomic
status persons whose risk is underestimated by FRS.
16 Recent
health reform legislation strengthening requirements for
collection of patient sociodemographic information coupled
with increasing use of area-based socioeconomic measures will
facilitate consideration of a range of CHD risk factors when
personalizing risk.
The above scenario is not farfetched. The UK, perhaps a
decade or so ahead of the US in EHR adoption in primary care,
provides a glimpse of future practice in the US.
17 SES is
incorporated into the most widely used risk assessment tool,
QRISK2.
18 Moreover, widespread use of EHRs in the UK has
facilitated establishment of prospective patient cohorts that
have yielded improved cardiovascular risk tools such as
QRISK2. These cohorts, often comprising more than a million
patients, and unimaginable in the pre-electronic age, have
made it possible to model CHD risk for relatively small ethnic
minority groups.
19 These huge samples derived from hundreds
of networked practices, also facilitate individualized estimates
of the benefits and harms associated with statin treatment.
20
Establishment of similar comparative effectiveness research
cohorts in the US will enable far more precisely personalized
risk assessment and treatment guidelines than has been
heretofore possible. Thus, Gordon et al.’s suggestion to begin
using the best available FRS prediction models with currently
available electronic devices seems timely.
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